Literature DB >> 8390409

Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA.

T Onda1, T Kanda, S Zanma, T Yasugi, S Watanabe, T Kawana, K Ueda, H Yoshikawa, Y Taketani, K Yoshiike.   

Abstract

Occurrence of the antibodies against human papillomavirus (HPV) 16 proteins E4 and E7 is specifically but independently associated with cervical cancer. To correlate HPV DNA and antibody data, we examined the biopsy specimens and sera, by polymerase chain reaction (PCR) and by ELISA, respectively, from 51 patients with cervical cancer (including 3 recurrent cases) and 22 with cervical intra-epithelial neoplasia. Consensus primers for the L1 region were used for PCR and bacterially expressed, purified fusion protein HPV-16 E4 and non-fusion protein HPV-16 E7 were used for ELISA. HPV-16 DNA and other HPV types were detected in 17 and 25, respectively, out of 51 cases of cervical cancer. Ten out of the 17 HPV-16-DNA-positives were positive either for anti-E4 or for anti-E7: positivities for anti-E4, for anti-E7, and for both were 6/17, 5/17 and 1/17 respectively. Three anti-E7-positives consisted of those for HPV-33, -52 and -58 DNA, suggesting that limited cross-reaction occurred between the HPV types. Among the HPV-16-DNA-positive cases of cancer, lymph-node or distant metastasis was recorded more frequently in the seropositives than in the seronegatives. Our results show that the HPV-16 anti-E4 or anti-E7 occurs in some, but not in all, of the HPV-16-DNA-positive cases, and support the hypothesis that the presence of the HPV-16 antibodies can be used as a marker for possible metastasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390409     DOI: 10.1002/ijc.2910540417

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; A Judd; A B Moscicki; A J Canchola; J F Hilton; J M Palefsky
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

2.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma.

Authors:  M F Baay; J M Duk; M P Burger; J Walboomers; J ter Schegget; K H Groenier; H W de Bruijn; E Stolz; P Herbrink
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

4.  Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females.

Authors:  K Matsumoto; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  Jpn J Cancer Res       Date:  1997-04

5.  Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer.

Authors:  Dolores Azucena Salazar-Piña; Adolfo Pedroza-Saavedra; Aurelio Cruz-Valdez; Eduardo Ortiz-Panozo; Minerva Maldonado-Gama; Lilia Chihu-Amparan; Angelica Nallelhy Rodriguez-Ocampo; Emilia Orozco-Fararoni; Fernando Esquivel-Guadarrama; Lourdes Gutierrez-Xicotencatl
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

6.  Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients.

Authors:  T Fujii; Y Matsushima; M Yajima; T Sugimura; M Terada
Journal:  Jpn J Cancer Res       Date:  1995-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.